Live Aarti Drugs Share Price Chart

O 516.45

H 516.45

L 516.45

VOL 80

Aarti Drugs Performance

Days Range

Low: ₹497.75
High: ₹518.00
Previous Close ₹516.10
Open ₹516.45
Volume 1,52,465
Day’s Range ₹497.75 - ₹518.00
52W Range ₹313.90 - ₹645.75
Market Cap ₹4,775.38 Cr

Aarti Drugs Fundamentals

ROCE (TTM) 15.3
P/E Ratio (TTM) 26.5
P/B Ratio 3.95
Industry P/E 36.55
Debt to Equity 0.49
ROE 14.9
EPS (TTM) 19.46
Dividend Yield 0.19
Book Value 130.68
Face Value 10

Aarti Drugs Financials

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales742.41661.11641.54605.94
Expenses661.37589.64577.71548.46
Profit before tax73.2863.5356.2751.55
Operating Profit56.1847.9739.636.71
Net Profit56.1847.9739.636.71
EPS in Rs6.075.184.293.99

About Aarti Drugs

History

Aarti Drugs Limited (ADL) is a major manufacturer of  Active Pharmaceutical Ingredients (APIs), formulations, and speciality chemicals. The company operates as part of the Aarti Group, which is a conglomerate. The company was incorporated in 1984. It was also listed on the BSE in 1993, and in the same year, it set up facilities for the production of glyoxal, i.e. the main raw material for imidazoles.  In 1998, the company’s yearly turnover crossed ₹100 crore. They provide over 50 compounds for antibiotics, anti-protozoal, anti-inflammatory, anti-diabetic, anti-fungal and cardioprotectant purposes. They have 2 R&D centres, one in Tarapur and the other in Turbhe, Maharashtra.

In 2003, the company also became listed on the NSE. In 2005-06, they entered into a joint venture with a Chinese company and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China.  In 2008, the company received approval for a facility from the USA’s Food and Drug Administration (FDA). 

In 2011, the company crossed a yearly turnover of ₹500 crore. Within 3 years, it doubled this amount by earning a turnover of ₹1,000 crore in 2014. During the year 2020, the company incorporated 2 overseas subsidiaries and 1 domestic subsidiary.  In 2022, the company commissioned a brownfield expansion of its speciality chemical plant at Tarapur, which became operational in May 2022. In 2023, the company crossed the standalone turnover of ₹2,500 crore.  The company is the largest producer of Metronidazole in India and of Tinidazole, Ketoconazole, and Fluoroquinolone formulations worldwide.

Business Segments

The company has the following business segments:

  1. Active Pharmaceutical Ingredients (APIs) – The company is a leading API producer of over 50 molecules for antibiotics, antiprotozoal, anti-inflammatory, antidiabetic and antifungal purposes. This segment contributed around 85% of the total revenue in FY 2023, based on 9 manufacturing units and 30 APIs developed in the 5 years preceding FY 2023.
  2. Formulations – For this segment, the company adopted a flexible manufacturing approach with the combination of in-house manufacturing as well as an outsourcing model supported by in-house R&D.
  3. Speciality Chemicals, Intermediates and others – This segment involves being a backward integrated approach, supplying intermediates of antibiotics, antifungal, anti-inflammatory and cardiovascular to the API manufacturers. In this segment, they have a special focus on Benzene and Chloro-sulphonic chemistry

Around 39% of the revenue came from exports in FY 2023.

Subsidiaries

As of March 31, 2023, Aarti Drugs has 3 subsidiaries: 

  1. Pinnacle Life Science Private Limited – Pinnacle Life Science Private Limited (PLSPL) is a wholly-owned subsidiary founded to become a global leader in high-quality and cost-effective pharmaceutical formulations.
  2. Aarti Speciality Chemicals Limited – This is a wholly-owned subsidiary dedicated to speciality chemicals.
  3. Pinnacle Chile SpA (a foreign subsidiary) -This company supports the marketing of medication formulations and participates in tenders in Santiago, Chile.

Key Personnel

Mr Prakash M. Patil, CMD and CEO

Mr Patil has 4 decades of experience in the chemical and pharmaceutical industry. He has expertise in the roles of product identification, project conceptualisation, planning, project engineering and implementation.

Mr Rashesh C. Gogri, Managing Director

Mr Rashesh C. Gogri has been appointed as the managing director of the company effective from September 26, 2014. He was the whole-time director of the company since October, 2012.

Corporate Actions

The company has performed the following corporate actions in recent years:

Bonus Issue

  1. It issued bonus shares at a 3:1 ratio with the record date of October 1, 2020.
  2. It issued bonus shares at a 1:1 ratio with the record date of March 25, 2015.

Share Buyback

  1. The company performed a buyback of its shares with a record date of August 4, 2023. 
  2. The company performed a buyback of its shares with the record date of April 1, 2021.
  3. The company performed a buyback of its shares with the record date of March 29, 2019.
  4. The company performed a buyback of its shares with the record date of January 19, 2018.
  5. The company performed a buyback of its shares with a record date of November 2, 2016.

Mergers and Acquisitions

  • In 2015, the company acquired 100% equity of Pinnacle Life Science Pvt Ltd. However, this subsidiary was wound up in 2021.
  • An amalgamation of a wholly owned subsidiary, Suyash Laboratories Ltd, into the company became operative effective from April 1, 2011.
  • In 1996, multiple companies were amalgamated into Aarti Drugs. These included Rupal Chemical Industries Ltd, Rashesh Chemicals & Pharmaceuticals Ltd, Manjarati Chemicals Pvt Ltd, Manjarati Plastisizer Pvt Ltd, Effective Chemicals Pvt Ltd, Star Aluminium Industries Ltd and Avez Wire Industries Ltd.
Parent Organisation Alchemie Group
Founded 1984
Managing Director Prakash M Patil
NSE Symbol AARTIDRUGS

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Supriya Lifescience Ltd ₹2,884.91

341.1

17.00 (-4.75%)

336.85 - 361.65
Celestial Biolabs Ltd ₹4.56

1.75

0.00 (0.00)

1.75 - 1.8
JFL Life Sciences Ltd ₹49.77

45.6

0.35 (0.77%)

45.6 - 47
Procter & Gamble Health Ltd ₹8,453.38

5089.25

8.85 (0.17%)

5050 - 5110.5
Veerhealth Care Ltd ₹47.34

26

0.00 (0.00)

26 - 26

What's Trending

Aarti Drugs FAQs

What is the Share price of Aarti Drugs (AARTIDRUGS)?

Aarti Drugs (AARTIDRUGS) share price as of February 28, 2024, on NSE is Rs 500.70 (NSE) and Rs 500.00 (BSE) on BSE.

Can I buy Aarti Drugs (AARTIDRUGS) shares?

Yes, You can buy Aarti Drugs (AARTIDRUGS) shares by opening a Demat account with Angel One.

How do I buy Aarti Drugs (AARTIDRUGS) from Angel One?

Aarti Drugs (AARTIDRUGS) share can be brought through the following modes:
  1. Direct investment: You can buy Aarti Drugs (AARTIDRUGS) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Aarti Drugs (AARTIDRUGS) shares.

Is Aarti Drugs a Debt free Company?

No, Aarti Drugs is not a debt free company.

What is the main business of Aarti Drugs?

The main business of Aarti Drugs is to manufacture and sell Active Pharmaceutical Ingredients (APIs), formulations, speciality chemicals, and pharma intermediates through its 12 GMP certified manufacturing plants.

Who are the promoters of Aarti Drugs?

Some of the main promoters of Aarti Drugs are Prakash Moreshwar Patil, Seema Harshit Savla, Harshit Manilal Savla, Rashesh Chandrakant Gogri, Priti Prakash Patil, Gogri Finserv Pvt. Ltd., Hetal Gogri Gala, Anushakti Enterprise Private Limited, Mirik Rajendra Gogri, and Renil Rajendra Gogri.

What are the Subsidiaries that comes under Aarti Drugs?

The main subsidiaries that come under Aarti Drugs are Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SpA.